Evidence map›Paper›PMID 42038146›Full record

ReviewGalen medical journal2024

Probiotics: Potential Benefits and Safety in Hematological Malignancies.

Mahdiyar Iravani Saadi, Mani Ramzi, Nastaran Fooladivanda, Sholeh Afshinpour, Zahra Ghahramani, Maryam Ahmadyan, Nadiya Kheradmand, Hourvash Haghighinejad, Zahra Rahimian

Abstract readReview
In one paragraph

Review in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mahdiyar Iravani SaadiHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mani RamziHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nastaran FooladivandaHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sholeh AfshinpourHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra GhahramaniHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam AhmadyanHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nadiya KheradmandHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hourvash HaghighinejadFamily Medicine Department, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra RahimianHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the most significant global health challenges, with increasing incidence and mortality rates and a substantial socioeconomic burden. Traditional cancer treatments such as chemotherapeutic drugs and radiation therapies, while effective, have significant adverse effects on the body, prompting the search for less invasive treatment options. In recent years, probiotics have emerged as a promising alternative in the prevention and treatment of cancer and its associated complications, especially in gastrointestinal malignancies. Probiotics have been found to have several beneficial effects on the body, including the ability to mitigate the gastrointestinal side effects of cancer treatments by restoring gut microbiota balance and improving intestinal barrier function. By reducing inflammation and enhancing the immune response, probiotics can also help alleviate other cancer-related symptoms and improve the overall well-being of cancer patients. Despite their potential benefits, the efficacy and safety of probiotics in immunocompromised patients remain uncertain, and caution must be exercised during their administration. Further research is needed to determine the optimal clinical use, safety, and efficacy of probiotics in cancer treatment.

Indexed as

ChemotherapyGVHDHematologic MalignancyHematopoietic Stem Cell TransplantationHSCTProbioticsRadiation Therapy

Identifiers

PMID42038146
PMCPMC11827882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.